Protein Engineering and Human Therapeutics
Advanced Medical Research Institute of Canada
Dr. Hanifi-Moghaddam received his Honours Bachelor of Science degree in Microbiology and Immunology from the University of Western Ontario in London, Ontario. He did his Ph.D. work at the German Diabetes Research Institute under the supervision of Professors Hubert Kolb and Nanette Schloot in Dusseldorf Germany and obtained his Ph.D. in Clinical Immunology from Leiden University in the Netherlands. He underwent postdoctoral training at the Josephine Cancer center, Erasmus University Medical Center in Rotterdam in the Netherlands and at the Research Institute of Molecular Pathology in Vienna, Austria. Dr. Hanifi-Moghaddam then joined the Antibody Engineering group at the Institute for Biological Sciences, National Research Council of Canada (NRC) in 2007 where he worked before joining the Advanced Medical Research Institute of Canada (AMRIC) in 2012. Dr Hanifi-Moghaddam is now a principal investigator at AMRIC. He is an Associate professor at the Northern Ontario School of medicine (NOSM) in the Faculty of Medicine at the Laurentian University and has a cross appointment, at the same rank, with the Faculty of Medicine at Lakehead University. He is also an Adjunct Professor at the School of Environmental Sciences, University of Guelph, and a Visiting Scientist in the Department of Biochemistry and Microbiology at the University of Ottawa.
Dr. Hanifi-Moghaddam’s interest is in developing novel and effective human therapeutics with a focus on cancer, diabetes and chronic diseases. His research specialty is developing antibodies to treat these diseases. More specifically, he focuses on antibody fragments that are either can be naturally isolated from certain species of camelids or cartilaginous fishes or can, alternatively, be synthesized by splitting the dimeric variable domains of immunoglobulin G (IgG) found in humans and other mammals. Despite the many significant advances that have been made in antibody technology, the identification and selection of soluble antibodies remains a time consuming and challenging task.